WuXi XDC Cayman Inc
HKSE: 2268.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jincai Li
- Employees
- 2,041
- Headquarters
- Wuxi, China
- IPO year
- 2012
- Market cap
- HK$70.6B
- Website
- https://wuxixdc.com
Loading 2268…
Loading profile data…Frequently asked questions about 2268
What does WuXi XDC Cayman Inc (2268.HK) do?
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-link...
Where does 2268.HK trade?
WuXi XDC Cayman Inc (2268.HK) trades on the Hong Kong Stock Exchange.
What sector is 2268.HK in?
WuXi XDC Cayman Inc (2268.HK) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of WuXi XDC Cayman Inc?
Jincai Li is the chief executive officer of WuXi XDC Cayman Inc (2268.HK).
Where is WuXi XDC Cayman Inc headquartered?
WuXi XDC Cayman Inc is headquartered in China.
Does 2268.HK pay a dividend?
WuXi XDC Cayman Inc (2268.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2268.HK go public?
WuXi XDC Cayman Inc (2268.HK) completed its initial public offering in 2012.